Clinical Trials
15 trialsNCT07616427 2026-06-01
TAYLOR-003
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07616453 2026-06-01
TAYLOR-002
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07618923 2026-06-01
TD-DASHER-01
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT07527806 2026-04-17
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT02630693 2026-04-13
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT07423611 2026-02-20
RACE
Fudan University
Phase 2 Not yet recruiting
NCT03624244 2026-02-17
BFR-ESS
Centre Leon Berard
Phase 2 Recruiting
NCT06970912 2026-01-21
DNADalHR
Peking University People's Hospital
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT04762979 2026-01-02
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Active not recruiting
NCT02760030 2025-12-19
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06107673 2025-12-11
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT06361940 2025-10-14
MAPPER
Medical College of Wisconsin
Phase 2 Recruiting
NCT04227327 2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2 Terminated
NCT04352777 2025-07-20
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Duke University
Phase 2 Completed